FilingReader Intelligence
Pharmaron announces 2024 results, new share award scheme
March 28, 2025 at 12:24 AM UTC•By FilingReader AI
Pharmaron Beijing (HKEX:3759) today announced its 2024 annual results, alongside proposals for a new share award scheme and amendments to its existing scheme, signaling a continued focus on growth and talent retention. The company reported revenue of RMB 12.28 billion, a 6.4% increase year-over-year, and profit attributable to owners of the parent of RMB 1.79 billion, a 12% increase. The Board has proposed a final dividend of RMB 2.0 per 10 shares for 2024.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
FINAL DIVIDEND IN CASH FOR THE YEAR ENDED DECEMBER 31, 2024March 26, 2025 at 12:43 PM UTC
(1)PROPOSED ADOPTION OF THE 2025 H SHARE AWARD SCHEME; (2)PROPOSED AMENDMENTS TO THE LIMIT OF THE EXISTING H SHARE AWARD SCHEME; (3)PROPOSED INCREASE IN THE REGISTERED CAPITAL; AND (4)PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATIONMarch 26, 2025 at 12:57 PM UTC
HKEX:3759•Hong Kong Exchange
News Alerts
Get instant email alerts when Pharmaron Beijing publishes news
Free account required • Unsubscribe anytime